trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Triptans and nonsteroidal anti-inflammatory drugs are used as treatments for episodic migraine.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Triptans and nonsteroidal anti-inflammatory drugs are used as treatments for episodic migraine?

Yes. Triptans and nonsteroidal anti-inflammatory drugs are well-established acute treatments utilized for episodic migraine management in clinical practice.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently confirm that both triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) are standard acute pharmacological interventions for episodic migraine. No papers refute this claim.

Evidence for · 4
Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine
2023
Identifies NSAIDs as widely used acute treatments for episodic migraine.
Get citation
Ezzati, A., Fanning, K. M., Reed, M. L., & Lipton, R. B. (2023). Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine. doi.org. https://doi.org/10.1111/head.14459

See more details
More for · 3
Knowledge, Attitude, and Practices of General Neurologists and Headache Experts Toward Migraine Treatment: A Cross-Sectional Study in India.
2026
Reports that nonsteroidal anti-inflammatory drugs and triptans are among the most commonly prescribed therapies for migraine.
Get citation
S, A., A, B., I, P., & V, M. (2026). Knowledge, Attitude, and Practices of General Neurologists and Headache Experts Toward Migraine Treatment: A Cross-Sectional Study in India.. doi.org. https://doi.org/10.4103/aian.aian_1225_25

Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.
2026
Discusses triptan use and subsequent reduction following preventive treatment in migraine patients.
Get citation
S, G., L, P., L, G., F, L. C., MC, O., L, D. E., & F, G. (2026). Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.. doi.org. https://doi.org/10.1186/s10194-026-02434-8

Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment.
2026
Reviews acute and preventive treatment strategies, confirming the therapeutic role of triptans and nonsteroidal anti-inflammatory drugs.
Get citation
W, L., Y, Z., C, S., Y, T., S, L., Y, S., F, J., D, J., TP, S., & J, T. (2026). Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment.. doi.org. https://doi.org/10.1002/mco2.70933

What does the evidence say?

The retrieved papers consistently confirm that both triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) are standard acute pharmacological interventions for episodic migraine. No papers refute this claim.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work